Saturday, July 11, 2026

Patent intelligence · US

US 8920848

Use of cellular extracts for skin rejuvenation

granted A61KA61K35/60A61K8/676A61K8/982
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 8
Applicant portfolio 8,292
Patent details — US 8920848
Jurisdiction
US
Status
granted
Grant date
Dec 30, 2014
Expiration
Dec 25, 2034
Applicant
REGENICS AS
Claims
20
CPC classes
A61K, A61K35/60, A61K8/676, A61K8/982
View on Google Patents ↗

Quick answer

US 8920848 (Use of cellular extracts for skin rejuvenation) is held by REGENICS AS. Status: granted. Granted Dec 30, 2014. Expires Dec 25, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
REGENICS AS
Grant date
Expiration
Claims
20
CPC classes
A61K, A61K35/60, A61K8/676, A61K8/982, A61K8/987

More from REGENICS AS

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 8920848?

US 8920848 (Use of cellular extracts for skin rejuvenation) is held by REGENICS AS. Status: granted. Granted Dec 30, 2014. Expires Dec 25, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8920848?

REGENICS AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 8920848 expire?

Our index shows an expiration date of Dec 25, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.